Platelet-related pathways

Platelet-related pathways encompass the complex series of biochemical and cellular events leading to platelet adhesion, activation, and aggregation at sites of vascular injury (StatPearls, 2023). These pathways are essential for normal hemostasis but also drive pathological thrombosis in cardiovascular diseases. Key molecular components include receptors like P2Y12, Glycoprotein IIb/IIIa, and PAR-1, as well as enzymes like Cyclooxygenase-1 (PubMed: 30135125). Pharmacological modulation of these pathways is a cornerstone of antiplatelet therapy to prevent myocardial infarction and stroke (PubMed: 28838302). However, balancing efficacy with the inherent risk of bleeding remains a primary clinical challenge in managing patients on these therapies (NIH, 2022). The pathways involve multiple feedback loops and redundant signaling mechanisms, which often necessitate dual antiplatelet therapy (DAPT) for high-risk patients to ensure adequate suppression of thrombotic events (PubMed: 24507071).

Other names

Platelet activation pathwayPlatelet aggregation pathwayHemostatic signalingThrombosis pathwaysPlatelet signaling cascades

Drugs targeting these pathways act through several distinct mechanisms: irreversible inhibition of cyclooxygenase-1 (COX-1) to block thromboxane A2 production; antagonism of the P2Y12 adenosine diphosphate (ADP) receptor to prevent secondary platelet activation; inhibition of the Glycoprotein IIb/IIIa receptor to block the final common pathway of platelet aggregation (fibrinogen binding); and antagonism of Protease-Activated Receptor-1 (PAR-1) to inhibit thrombin-mediated platelet effects (StatPearls, 2023; PubMed: 28838302).